HomeCompareNTEC vs CHD

NTEC vs CHD: Dividend Comparison 2026

NTEC yields 20.77% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NTEC wins by $50.2K in total portfolio value
10 years
NTEC
NTEC
● Live price
20.77%
Share price
$9.63
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$7,308.86
Full NTEC calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — NTEC vs CHD

📍 NTEC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTECCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTEC + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTEC pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTEC
Annual income on $10K today (after 15% tax)
$1,765.32/yr
After 10yr DRIP, annual income (after tax)
$6,212.53/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, NTEC beats the other by $5,113.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTEC + CHD for your $10,000?

NTEC: 50%CHD: 50%
100% CHD50/50100% NTEC
Portfolio after 10yr
$51.4K
Annual income
$4,300.68/yr
Blended yield
8.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

NTEC
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTEC buys
0
CHD buys
0
No recent congressional trades found for NTEC or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTECCHD
Forward yield20.77%1.27%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$76.5K$26.4K
Annual income after 10y$7,308.86$1,292.51
Total dividends collected$44.4K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: NTEC vs CHD ($10,000, DRIP)

YearNTEC PortfolioNTEC Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$12,777$2,076.84$10,856$156.32+$1.9KNTEC
2$16,151$2,479.95$11,811$195.24+$4.3KNTEC
3$20,212$2,929.82$12,883$244.38+$7.3KNTEC
4$25,053$3,426.51$14,091$306.64+$11.0KNTEC
5$30,776$3,969.42$15,463$385.88+$15.3KNTEC
6$37,488$4,557.19$17,033$487.17+$20.5KNTEC
7$45,300$5,187.86$18,843$617.36+$26.5KNTEC
8$54,329$5,858.83$20,947$785.72+$33.4KNTEC
9$64,699$6,567.01$23,419$1,004.91+$41.3KNTEC
10$76,537$7,308.86$26,350$1,292.51+$50.2KNTEC

NTEC vs CHD: Complete Analysis 2026

NTECStock

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.

Full NTEC Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this NTEC vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTEC vs SCHDNTEC vs JEPINTEC vs ONTEC vs KONTEC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.